206 related articles for article (PubMed ID: 26232187)
1. Comparing probabilistic and descriptive analyses of time-dose-toxicity relationship for determining no-observed-adverse-effect level in drug development.
Glatard A; Berges A; Sahota T; Ambery C; Osborne J; Smith R; Hénin E; Chen C
Toxicol Appl Pharmacol; 2015 Oct; 288(2):240-8. PubMed ID: 26232187
[TBL] [Abstract][Full Text] [Related]
2. In Silico Models for Repeated-Dose Toxicity (RDT): Prediction of the No Observed Adverse Effect Level (NOAEL) and Lowest Observed Adverse Effect Level (LOAEL) for Drugs.
Pizzo F; Benfenati E
Methods Mol Biol; 2016; 1425():163-76. PubMed ID: 27311467
[TBL] [Abstract][Full Text] [Related]
3. Implementing Toxicity Testing in the 21st Century (TT21C): Making safety decisions using toxicity pathways, and progress in a prototype risk assessment.
Adeleye Y; Andersen M; Clewell R; Davies M; Dent M; Edwards S; Fowler P; Malcomber S; Nicol B; Scott A; Scott S; Sun B; Westmoreland C; White A; Zhang Q; Carmichael PL
Toxicology; 2015 Jun; 332():102-11. PubMed ID: 24582757
[TBL] [Abstract][Full Text] [Related]
4. A statistical evaluation of toxicity study designs for the estimation of the benchmark dose in continuous endpoints.
Slob W; Moerbeek M; Rauniomaa E; Piersma AH
Toxicol Sci; 2005 Mar; 84(1):167-85. PubMed ID: 15483190
[TBL] [Abstract][Full Text] [Related]
5. A benchmark dose analysis for sodium monofluoroacetate (1080) using dichotomous toxicity data.
Foronda NM; Fowles J; Smith N; Taylor M; Temple W
Regul Toxicol Pharmacol; 2007 Feb; 47(1):84-9. PubMed ID: 16965845
[TBL] [Abstract][Full Text] [Related]
6. Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose.
Contrera JF; Matthews EJ; Kruhlak NL; Benz RD
Regul Toxicol Pharmacol; 2004 Dec; 40(3):185-206. PubMed ID: 15546675
[TBL] [Abstract][Full Text] [Related]
7. Principles of risk assessment for determining the safety of chemicals: recent assessment of residual solvents in drugs and di(2-ethylhexyl) phthalate.
Hasegawa R; Koizumi M; Hirose A
Congenit Anom (Kyoto); 2004 Jun; 44(2):51-9. PubMed ID: 15198717
[TBL] [Abstract][Full Text] [Related]
8. Study parameters influencing NOAEL and LOAEL in toxicity feeding studies for pesticides: exposure duration versus dose decrement, dose spacing, group size and chemical class.
Zarn JA; Engeli BE; Schlatter JR
Regul Toxicol Pharmacol; 2011 Nov; 61(2):243-50. PubMed ID: 21875639
[TBL] [Abstract][Full Text] [Related]
9. The benchmark dose method--review of available models, and recommendations for application in health risk assessment.
Filipsson AF; Sand S; Nilsson J; Victorin K
Crit Rev Toxicol; 2003; 33(5):505-42. PubMed ID: 14594105
[TBL] [Abstract][Full Text] [Related]
10. Bootstrap estimation of benchmark doses and confidence limits with clustered quantal data.
Zhu Y; Wang T; Jelsovsky JZ
Risk Anal; 2007 Apr; 27(2):447-65. PubMed ID: 17511711
[TBL] [Abstract][Full Text] [Related]
11. Standard and molecular NOAELs for rat testicular toxicity induced by flutamide.
Rouquié D; Friry-Santini C; Schorsch F; Tinwell H; Bars R
Toxicol Sci; 2009 May; 109(1):59-65. PubMed ID: 19299419
[TBL] [Abstract][Full Text] [Related]
12. A molecular and phenotypic integrative approach to identify a no-effect dose level for antiandrogen-induced testicular toxicity.
Ludwig S; Tinwell H; Schorsch F; Cavaillé C; Pallardy M; Rouquié D; Bars R
Toxicol Sci; 2011 Jul; 122(1):52-63. PubMed ID: 21525395
[TBL] [Abstract][Full Text] [Related]
13. Deriving a data-based interspecies assessment factor using the NOAEL and the benchmark dose approach.
Bokkers BG; Slob W
Crit Rev Toxicol; 2007 Jun; 37(5):355-73. PubMed ID: 17612951
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the dose decrement in regulatory rat pesticide toxicity feeding studies.
Zarn JA; Engeli BE; Schlatter JR
Regul Toxicol Pharmacol; 2013 Nov; 67(2):215-20. PubMed ID: 23911766
[TBL] [Abstract][Full Text] [Related]
15. Benchmark dose calculation for ordered categorical responses.
Chen CC; Chen JJ
Risk Anal; 2014 Aug; 34(8):1435-47. PubMed ID: 24444309
[TBL] [Abstract][Full Text] [Related]
16. Quantalization of continuous data for benchmark dose estimation.
Gaylor DW
Regul Toxicol Pharmacol; 1996 Dec; 24(3):246-50. PubMed ID: 8975754
[TBL] [Abstract][Full Text] [Related]
17. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
EFSA GMO Panel Working Group on Animal Feeding Trials
Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
[TBL] [Abstract][Full Text] [Related]
18. A probabilistic framework for non-cancer risk assessment.
Chen JJ; Moon H; Kodell RL
Regul Toxicol Pharmacol; 2007 Jun; 48(1):45-50. PubMed ID: 17166641
[TBL] [Abstract][Full Text] [Related]
19. Acute and subchronic oral toxicity of Coriolus versicolor standardized water extract in Sprague-Dawley rats.
Hor SY; Ahmad M; Farsi E; Lim CP; Asmawi MZ; Yam MF
J Ethnopharmacol; 2011 Oct; 137(3):1067-76. PubMed ID: 21767625
[TBL] [Abstract][Full Text] [Related]
20. The use of myocardial and testicular end points as a basis for estimating a proposed tolerable daily intake for sodium monofluoroacetate (1080).
Foronda NM; Fowles J; Smith N; Taylor M; Temple W; Darlington C
Regul Toxicol Pharmacol; 2007 Feb; 47(1):29-36. PubMed ID: 17030370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
